Odyssean LLC Invests $1.17 Million in Inspire Medical Systems, Inc. $INSP

Odyssean LLC acquired a new position in Inspire Medical Systems, Inc. (NYSE:INSP) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 26,282 shares of the company’s stock, valued at approximately $1,172,000.

Other hedge funds and other institutional investors have also modified their holdings of the company. Royal Bank of Canada increased its position in Inspire Medical Systems by 16.0% in the first quarter. Royal Bank of Canada now owns 32,769 shares of the company’s stock worth $5,220,000 after purchasing an additional 4,528 shares during the period. Integrated Wealth Concepts LLC bought a new stake in shares of Inspire Medical Systems in the 1st quarter valued at about $524,000. Goldman Sachs Group Inc. raised its position in shares of Inspire Medical Systems by 57.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 51,422 shares of the company’s stock valued at $8,190,000 after acquiring an additional 18,857 shares during the period. Marshall Wace LLP increased its position in shares of Inspire Medical Systems by 3.8% in the 2nd quarter. Marshall Wace LLP now owns 15,905 shares of the company’s stock valued at $2,064,000 after buying an additional 577 shares in the last quarter. Finally, Jump Financial LLC acquired a new stake in Inspire Medical Systems during the 2nd quarter worth $931,000. Institutional investors and hedge funds own 94.91% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on INSP shares. JPMorgan Chase & Co. increased their target price on Inspire Medical Systems from $54.00 to $60.00 and gave the stock a “neutral” rating in a report on Tuesday, August 4th. Royal Bank Of Canada reaffirmed a “sector perform” rating and set a $60.00 price target on shares of Inspire Medical Systems in a research report on Tuesday, August 4th. Robert W. Baird raised their price objective on Inspire Medical Systems from $54.00 to $59.00 and gave the company a “neutral” rating in a research report on Tuesday, August 4th. Summit Redstone set a $39.00 target price on shares of Inspire Medical Systems in a report on Friday, May 22nd. Finally, Freedom Capital raised Inspire Medical Systems to a “strong-buy” rating in a report on Tuesday, June 30th. Two equities research analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating, eleven have issued a Hold rating and three have assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $66.19.

Insider Activity at Inspire Medical Systems

In other news, insider Jason Kelly sold 963 shares of the stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $59.55, for a total value of $57,346.65. Following the completion of the sale, the insider owned 18,985 shares of the company’s stock, valued at approximately $1,130,556.75. This represents a 4.83% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 2.20% of the company’s stock.

Inspire Medical Systems Trading Up 1.4%

Shares of Inspire Medical Systems stock opened at $62.99 on Friday. The firm has a market capitalization of $1.82 billion, a PE ratio of 13.63, a price-to-earnings-growth ratio of 4.72 and a beta of 0.70. The firm’s 50 day moving average is $55.05 and its 200 day moving average is $52.43. Inspire Medical Systems, Inc. has a 1 year low of $38.91 and a 1 year high of $147.03.

Inspire Medical Systems (NYSE:INSP) last released its quarterly earnings data on Monday, August 3rd. The company reported $0.14 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.38. The business had revenue of $200.58 million during the quarter, compared to analysts’ expectations of $194.72 million. Inspire Medical Systems had a net margin of 15.03% and a return on equity of 8.64%. The firm’s quarterly revenue was down 7.6% compared to the same quarter last year. During the same period in the prior year, the company earned $0.45 EPS. Inspire Medical Systems has set its FY 2026 guidance at 1.050-1.450 EPS. As a group, research analysts anticipate that Inspire Medical Systems, Inc. will post 1.24 earnings per share for the current year.

Inspire Medical Systems Profile

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.